1. A Sub-Micromolar MraYAA Inhibitor with an Aminoribosyl Uridine Structure and a (S,S)-Tartaric Diamide: Synthesis, Biological Evaluation and Molecular Modeling
- Author
-
Martin Oliver, Laurent Le Corre, Mélanie Poinsot, Michaël Bosco, Hongwei Wan, Ana Amoroso, Bernard Joris, Ahmed Bouhss, Sandrine Calvet-Vitale, Christine Gravier-Pelletier, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Université de Liège, Structure et activité des biomolécules normales et pathologiques (SABNP), Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, and Bouhss, Ahmed
- Subjects
inhibitors synthesis ,inhibition tests ,[CHIM.THER] Chemical Sciences/Medicinal Chemistry ,Organic Chemistry ,Pharmaceutical Science ,[CHIM.THER]Chemical Sciences/Medicinal Chemistry ,Analytical Chemistry ,MraY transferase ,carbacaprazamycin analogs ,molecular docking studies ,Chemistry (miscellaneous) ,Drug Discovery ,Molecular Medicine ,Physical and Theoretical Chemistry - Abstract
International audience; New inhibitors of the bacterial tranferase MraY are described. Their structure is based on an aminoribosyl uridine scaffold, which is known to be important for the biological activity of natural MraY inhibitors. A decyl alkyl chain was introduced onto this scaffold through various linkers. The synthesized compounds were tested against the MraYAA transferase activity, and the most active compound with an original (S,S)-tartaric diamide linker inhibits MraY activity with an IC50 equal to 0.37 µM. Their antibacterial activity was also evaluated on a panel of Gram-positive and Gram-negative strains; however, the compounds showed no antibacterial activity. Docking and molecular dynamics studies revealed that this new linker established two stabilizing key interactions with N190 and H325, as observed for the highly potent inhibitors carbacaprazamycin, muraymycin D2 and tunicamycin.
- Published
- 2022
- Full Text
- View/download PDF